EP0106565B1 — Leukotriene antagonists, their production, and compositions containing them
Assigned to Merck Frosst Canada and Co · Expires 1986-09-10 · 40y expired
What this patent protects
Compounds of the formulae: <CHEM> and their pharmaceutically acceptable (including acid-addition) salts, which are novel, are antagonists of leukotrienes of C4, D4 and E4, the slow reacting substance of anaphylaxis. They can be made into pharmaceutical compositions by incor…
USPTO Abstract
Compounds of the formulae: <CHEM> and their pharmaceutically acceptable (including acid-addition) salts, which are novel, are antagonists of leukotrienes of C4, D4 and E4, the slow reacting substance of anaphylaxis. They can be made into pharmaceutical compositions by incorporating them in a pharmaceutical carrier. In the formulae, each R is H, OH, SH C1 6 alkyl C2 6 alkenyl, CF3, C1 6 alkoxy, C1 6 alkylthio, benzyl, phenethyl, halogen, amino, N(R4)2, COOR4 or CH2OR4 where R4 is H or C1 6 alkyl, formyl, CN, CF3S or NO2; each R min is R4; OR4; COOR4; N(R4)2; SR4; CH2OR4 or CHO; or together R min and R min are O, CH2 or <CHEM> Y min is sulfur, sulfoxide, sulfone, @ = NR11, = NR12, = N - CO - R13, - N - CN, CH2 or C = 0 where R11 is H, C1-4 alkyl, C1 4 alkanoyl, phenylsulfonyl or p-toluenesulfonyl, R12 is H or C1-4 alkyl and R13 is C1-4 alkyl or C1-4 alkoxy; Y is of the type defined for Y min or oxygen; each R1 is hydrogen C1-3 alkyl; each m is 0 or an integer from 1 to 6; <CHEM> where each R6 is H or C1-4 alkyl; each R7 is H, OH or C1-4 alkyl; and each R8 is H or C1-4 alkyl and is absent when the two indicated carbons are triply bonded; R5 is COOR4; CH2OH, CHO: tetrazole; NHSO2R14; CONHSO2R14; hydroxymethylketone; CN; CON(R7)2; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR15 where R15 is: <CHEM> where each s is independently 0-3, R6 is as defined above and R16 is (A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 N heteroatoms or one N and one S heteratom, each ring in the heterocyclic radical being formed of 5 or 6 atoms, or (B) W-R17 where W is O, S or NH and R17 contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical or an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring; each of r and q is 0-20 but r + q does not exceed 20; and p is 0 or 1; R3 is C1-6 alkyl or C3-6 alkenyl; R9 is C1-6 alkyl, C1 6 alkoxy or (CH2)rR5, where r and R5 are as defined above; and R10 is H, C1-6 alkyl; R4CO- or R4OCH2, where R4 is as defined above and R14 is OH, C1-6 alkoxy, C1-6 acyl, phenyl, phenyl having C1-3 alkyl or C1-3 alkoxy substitution, halogen, halogenated alkyl, carboxy, cyano or formyl.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.